Back to results
US 2003/0153075 A1Published application
TGF-beta-specific covalently closed antisense molecule
AssigneeWelgene Pharmaceuticals, Inc.
InventorsJong-Gu Park, Ik-Jae Moon, Young-Kook Choi, Kwankyu Park
Life of this patent
Estimating the term…
Abstract
The present application describes a purified covalently closed antisense molecule, which specifically inhibits expression of TGF-β.
Claims20
A purified covalently closed antisense molecule, which specifically inhibits expression of TGF-β.
A composition comprising a covalently closed antisense molecule, tat or tat-like peptide, and a carrier composition.
A method of delivering a covalently closed antisense molecule to a cell, comprising contacting the cell with the covalently closed antisense molecule, a tat or tat-like peptide and a carrier composition.
Dependencies are inferred from the claim text.